Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of phase 1 of this study is to establish the recommended phase II dose
(RP2D). The primary objective of phase 2 of this study is to evaluate the safety and efficacy
of bendamustine at the recommended pediatric dose for the treatment of pediatric patients
with relapsed or refractory acute leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.